Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | BCHE | P06276 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | BACE1 | P56817 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3887454 | 0.89 | ALDH1A1 (0.57) | ALDH1A1BCHEACHEBACE1SIGMAR1 | |
| SCHEMBL12642582 | 0.83 | RAB9A (0.60) | RAB9AMEN1ALDH1A1CYP2D6KMT2A | |
| SCHEMBL4141085 | 0.83 | ALDH1A1 (0.60) | RAB9AMEN1ALDH1A1CYP2D6KMT2A | |
| SCHEMBL1457116 | 0.82 | HTR2A (0.64) | HTR2A | |
| SCHEMBL1505926 | 0.82 | — | — | |
| SCHEMBL8117468 | 0.82 | MAPT (0.67) | SIGMAR1 | |
| SCHEMBL8244953 | 0.81 | ALDH1A1 (0.65) | RAB9AMEN1ALDH1A1CYP2D6KMT2A | |
| SCHEMBL3158673 | 0.81 | ALDH1A1 (0.61) | RAB9AMEN1ALDH1A1CYP2D6KMT2A | |
| SCHEMBL4700996 | 0.81 | ALDH1A1 (0.60) | RAB9AMEN1ALDH1A1CYP2D6KMT2A | |
| SCHEMBL29088753 | 0.81 | ALDH1A1 (0.56) | RAB9AMEN1ALDH1A1CYP2D6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2023010078-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2021158698-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| CN-1084329-C | Benzyl piepridine derivs as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2002-05-08 | — | — | CN | disclosed |
| EP-0760368-B1 | PYRIMIDINE DERIVATIVES | NISSHIN FLOUR MILLING CO (JP) | 1999-07-28 | — | — | EP | disclosed |
| EP-0871613-A1 | BENZYL PIPERIDINE DERIVATIVES AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 1998-10-21 | — | — | EP | disclosed |
| CN-1183768-A | Benzyl piepridine derivs as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 1998-06-03 | — | — | CN | disclosed |
| US-5753679-A | SCIZOPHRENIA | HOFFMANN-LA ROCHE INC. (US) | 1998-05-19 | — | — | US | disclosed |
| US-5736550-A | TREATMENT OF GASTROINTESTINAL TRACT DISORDERS | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1998-04-07 | — | — | US | disclosed |
| EP-0760368-A1 | NOVEL PYRIMIDINE DERIVATIVE | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1997-03-05 | — | — | EP | disclosed |
| WO-1996035666-A1 | BENZYL PIPERIDINE DERIVATIVES AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 1996-11-14 | — | — | WO | disclosed |
| US-4639522-A | HYPOTENSIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1987-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | RAB9A 3190/4885MEN1 1049/4885ALDH1A1 1378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.